PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$59.17
−2.98%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$61.70
From 52W high−33.93%
Volume774825.00
Market cap$4.94B
P/E (TTM)—
P/S (TTM)4.9x
Div yield—
Key dataOct 16, 2026
Open
$61.70
From 52W high
−33.93%
Volume
774825.00
Market cap
$4.94B
ValuationView details →
P/E (Fwd)
37.2x
EV/EBITDA
19.6x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
−2.98%
YTD Return
−21.79%
SummaryUpdated Jun 1, 2026
PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biopharmaceutical company founded in 1998 and headquartered in South Plainfield, New Jersey. The company went public in June 2013 and has evolved from a research-focused organization into a commercial-stage biopharmaceutical company with multiple marketed products. PTC specializes in discovering, developing, and commercializing treatments for rare diseases, with a particular focus on genetic disorders that affect small patient populations with high unmet medical needs.
Similar companies
Latest newsMore news →
Sangamo Therapeutics sold substantially all assets related to its gene therapy candidate ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111 million in cash at closing, up to $100 million in contingent milestones, and assumption of specified liabilities.25d agoPTC Therapeutics agreed to acquire from Sangamo Therapeutics all rights to ST-920, an AAV gene therapy product candidate for Fabry disease, for an upfront payment of $111 million plus up to $100 million in contingent milestone payments.49d agoPTC Therapeutics announced a planned acquisition of Sangamo Therapeutics' BLA-stage ST-920 Fabry disease gene therapy program, leveraging existing regulatory and commercial infrastructure.65d ago